SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Victrex plc - Q3 Interim Management Statement

6 Jul 2023 07:00

RNS Number : 1185F
Victrex PLC
06 July 2023
 
 

 

6 July 2023

Victrex plc - Q3 Interim Management Statement

Volumes lower on macro-economic weakness; further price improvement

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and bring environmental and societal benefit in multiple end-markets. Today's Interim Management Statement for Q3 covers the period 1 April 2023 to 30 June 2023.

Performance summary - Q3 in line with guidance

As previously communicated in our trading update of 14 June 2023 and at our interim results, compared to a record prior year period, the Group is seeing ongoing macro-economic weakness and destocking across several end markets.

The Group continues to be well positioned for a macro-economic recovery.

Q3 saw further improvement in average selling prices (ASP), taking year-to-date ASP to £85/kg, supported by price increases, sales mix and currency. We now anticipate that full year ASP will be above £84/kg. This in turn, together with easing energy costs, means we are seeing gross margin improvement during the second half, compared to the prior year, but it will be slightly held back by lower asset utilisation.

Further progress in mega-programmes; E-mobility exceeding expectations

Further progress was seen in commercial milestones within our 'mega-programme' growth pipeline, particularly in E-mobility and Trauma. We now anticipate annual revenues in our E-mobility mega-programme will exceed our original expectations, reaching £5m in FY 2023. In Trauma, we are making good progress with our PEEK composite Trauma plates, serving growing demand in the US and Asia. Run-rates are building towards £1m revenue and further growth in both E-mobility and Trauma is expected in FY 2024.

Q3 performance:

· Q3 Group revenue down 23% to £72.2m (Q3 2022: £93.4m)

· Q3 Group volume down 38% to 818 tonnes (Q3 2022: 1,323 tonnes)

· Year to date Group revenue of £234.4m is 8% down on the prior year (2022 YTD: £253.5m), with YTD Group volume of 2,759 tonnes being 23% down on the prior year (2022 YTD: 3,586 tonnes)

· Q3 weakness driven by Electronics, Energy & Industrial and Value Added Resellers

· Aerospace seeing good growth; Automotive stable YTD

· Medical performing strongly; YTD revenue continues to track up double-digit

 

 

 

Financial position

Victrex retains a highly cash generative business model, which supports growth investment and shareholder returns. Capital expenditure this year is focused on our China manufacturing investments, with our new PEEK polymer facility having delivered first polymer ahead of commercial start up by the end of 2023. Total cash on 30 June 2023 was £27m, which includes £3.5m cash ringfenced in China investments. Capital expenditure will start to step down from FY 2024, supporting improving cashflows.

 

Outlook unchanged

Jakob Sigurdsson, Chief Executive of Victrex, said: "In line with our recent trading update, we continue to be impacted by ongoing macro-economic weakness and destocking in several end markets. Compared to a record prior year period, lower Q3 volumes were driven by Electronics, Energy & Industrial and Value Added Resellers. Aerospace and Medical continue to perform strongly, whilst Automotive is stable year-to-date.

 

"Overall, our Outlook is unchanged from what we recently communicated, with full-year adjusted (pre-exceptional) PBT expected to be in the range of £80m-£85m. As we move into the final quarter, strong average selling prices, mix, energy costs and cost discipline remain supportive, and we continue to be well-placed for when the macro-economic environment improves.

 

"On a medium to long term basis, we have a strong and diverse core business, growing commercialisation in our mega-programmes, capital investment which is set to reduce and support improving cash flows, and strong ESG credentials."

 

Victrex will report its Preliminary Results for 2023 on Tuesday 4 December 2023.

 

Analyst & investor call:

A call for analysts & investors will be held today, Thursday 6 July, at 08.30am UK time. To register for the call please follow this link:

https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=3197336&linkSecurityString=82f3181b0

 

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTBCGDRISGDGXU
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.